Food and Drug Administration, HHS

§864.7280 Factor V Leiden DNA mutation detection systems.

- (a) Identification. Factor V Leiden deoxyribonucleic acid (DNA) mutation detection systems are devices that consist of different reagents and instruments which include polymerase chain reaction (PCR) primers, hybridization matrices, thermal cyclers, imagers, and software packages. The detection of the Factor V Leiden mutation aids in the diagnosis of patients with suspected thrombophilia.
- (b) Classification. Class II (special controls). The special control is FDA's guidance entitled "Class II Special Controls Guidance Document: Factor V Leiden DNA Mutation Detection Systems." (See §864.1(d) for the availability of this guidance document.)

[69 FR 12273, Mar. 16, 2004]

§864.7290 Factor deficiency test.

- (a) Identification. A factor deficiency test is a device used to diagnose specific coagulation defects, to monitor certain types of therapy, to detect coagulation inhibitors, and to detect a carrier state (a person carrying both a recessive gene for a coagulation factor deficiency such as hemophilia and the corresponding normal gene).
- (b) Classification. Class II (performance standards).

[45 FR 60613, Sept. 12, 1980]

§ 864.7300 Fibrin monomer paracoagulation test.

- (a) Identification. A fibrin monomer paracoagulation test is a device used to detect fibrin monomer in the diagnosis of disseminated intravascular coagulation (nonlocalized clotting within a blood vessel) or in the differential diagnosis between disseminated intravascular coagulation and primary fibrinolysis (dissolution of the fibrin in a blood clot).
- (b) Classification. Class II. The special control for this device is FDA's "In Vitro Diagnostic Fibrin Monomer Paracoagulation Test."
- $[45\ {\rm FR}\ 60614,\ {\rm Sept.}\ 12,\ 1980,\ {\rm as}\ {\rm amended}\ {\rm at}\ 52\ {\rm FR}\ 17733,\ {\rm May}\ 11,\ 1987;\ 65\ {\rm FR}\ 17144,\ {\rm Mar.}\ 31,\ 2000]$

§864.7320 Fibrinogen/fibrin degradation products assay.

- (a) Identification. A fibrinogen/fibrin degradation products assay is a device used to detect and measure fibrinogen degradation products and fibrin degradation products (protein fragments produced by the enzymatic action of plasmin on fibrinogen and fibrin) as an aid in detecting the presence and degree of intravascular coagulation and fibrinolysis (the dissolution of the fibrin in a blood clot) and in monitherapy for disseminated intravascular coagulation (nonlocalized clotting in the blood vessels).
- (b) Classification. Class II (performance standards).

[45 FR 60615, Sept. 12, 1980]

§864.7340 Fibrinogen determination system.

- (a) Identification. A fibrinogen determination system is a device that consists of the instruments, reagents, standards, and controls used to determine the fibrinogen levels in disseminated intravascular coagulation (non-localized clotting within the blood vessels) and primary fibrinolysis (the dissolution of fibrin in a blood clot).
- (b) Classification. Class II (performance standards).

[45 FR 60615, Sept. 12, 1980]

$\$\,864.7360$ Erythrocytic glucose-6-phosphate dehydrogenase assay.

- (a) Identification. An erythrocytic glucose-6-phosphate dehydrogenase assay is a device used to measure the activity of the enzyme glucose-6-phosphate dehydrogenase or of glucose-6phosphate dehydrogenase isoenzymes. The results of this assay are used in diagnosis and treatment of nonspherocytic congenital hemolytic anemia or drug-induced hemolytic anemia associated with a glucose-6-phosphate dehydrogenase deficiency. This generic device includes assays based on electrophoresis. fluorescence. methemoglobin reduction, catalase inhibition, and ultraviolet kinetics.
- (b) Classification. Class II (performance standards).

[45 FR 60616, Sept. 12, 1980]